[Interstitial lung disease in a patient given gemcitabine].
The differential diagnosis between infectious complications and tumor progression is sometimes difficult in patients given cytotoxic drugs. We report a case of diffuse interstitial lung disease induced by gemcitabine, a new agent used for the treatment of advanced-stage non-small-cell lung cancer.
Hammerer
V
V
Service de Pneumologie, Hôpital Lyautey, Hôpitaux Universitaires de Strasbourg, 1, rue des Canonniers, 67100 Strasbourg.
Schmitz
N
N
Pauli
G
G
Quoix
E
E
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D018450:Disease Progression; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000175:diagnosis; D014057:Tomography, X-Ray Computed; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine